Viking therapy today
Viking therapy
As of 04.25.2025 21:00
- 52-week range
- $ 18.92
▼
$ 81.86
- Value is valuable
- $ 89.50
Viking Therapeutics Inc. NASDAQ: VKTX Profit after the closure of the market is reported on April 23.The rally field moves higher, as investors are trying to figure out the report in which there were no real news that investors did not hear.
The company that is still in Preliminary stageIt is reported about the negative profit for the action in the 41st Center. This was lower than the negative 34 cents per promotion that analysts awaited, and below the negative 27 cents per share, which he provided in the same quarter in 2024. The company also reported a small lack of its funds, cash equivalents and short -term investments up to $ 852 million. USA.
The cause of the decline was quite simple. The company spent more money for production costs for drug candidates and clinical trials. Financial indicators showed that he also spent more on higher compensation based on shares and salary.
In this case there is no news
Promotions of the Vikings of therapy have risen higher In March, after the company published the results of its 13-week research for its candidate in GLP-1 VK2735. The study showed that the participants reached 13.1% weight loss loss of placeboField
It was faster than Zepbound and WegovyCurrent medicines for obesity GLP-1 from Eli Lilly & Co. NYSE: Lly and novo nordisk a/s NYSE: NVOrespectively. And the company announced that in this quarter the testing of the phase 3 for VK2735 began.
Viking also tests the oral version of VK2735, which, although the study has just begun now, can change the situation for patients who want to avoid painful injections. Company Predicts data From a study that will be available somewhere in the second half of the year.
Nevertheless, Viking is in the race to deliver its oral version to the market. Despite the fact that he has an advantage, larger companies that collaborate with other biotechnics can pass by.
Nevertheless, the wider news was that the VK2735 reached the 171-day half-life. This means that the drug can administer once a month instead of the current weekly injection standard.
Many patients express the desire for less frequent dosing, either for cost reasons, or by discomfort with injections. It can also solve insurance on how health insurers, especially Medicare and Medicaid, will make a decision on compensation.
Viking has other candidates in their pipeline
Any conversation about the Vikings last year was focused on its GLP-1 candidates and not for good reasons. Obesity of drugs were among Several places where investors could achieve solid growthField
However, the company has two additional drugs that continue to take place at the clinical test stage. VK2809 is the treatment of NASH/MASH, which provided successful primary and secondary endpoints in the 2B phase study. The company also has VK0214, which is aimed at rare diseases.
You can wait for VKTX shares, but he has it in the observation list
Viking Therapeutics Promotions Today today
$ 89.50
258.14% growthModerate purchase
Based on 13 analysts ratings
| The current price | $ 24.99 |
|---|---|
| High forecast | $ 138.00 |
| Average forecast | $ 89.50 |
| Low forecast | $ 30.00 |
Details of the forecast of viking funds
VKTX Promotions made a quick trip to the toilet at non -working hours before increasing. This could reflect the idea that the report was already baked in the price of shares, which in five days at the age of more than 7% The end of April 23.
IN $ 25.84The stock is within the limits of the share 50-day simple sliding average (SMA) for about $ 27.11. The passage of this level can begin a longer rally. But without any new news, most likely at the current level, especially with a short percentage, it still exceeds 24% for shares.
However, this can be a signal for investors to take part. Investing in medical actions is inaccurate science. And there is no guarantee that Viking will be able to bring their candidates to the market. However, Promotions can shoot much higher If the company provides a favorable indication of its phase 2 test for the oral version of VK2735.
This means that there is no need to urgently rush to full position. Nevertheless, for investors who believe that VK2735 will be approved and can change the rules of the game that many expect, It is worth continuing the observation list To keep up with clinical testing updates.
Before considering the Viking therapy, you will want to hear it.
Marketbeat monitors the highest and most effective analysts with the most effective Wall Street analysts and promotions that they recommend to their customers daily. Marketbeat has identified five shares that leading analysts quietly whisper to their clients to buy now before the wider market wins … and there was no wiking therapy on the list.
While Viking Therapeutics currently has a moderate purchase rating among analysts, analysts with the highest rating believe that these five promotions are better buying.
View five shares here
Marketbeat analysts have just released their five best short plays for May 2025. Find out what shares have the shortest interest and how to trade them. Enter your email address to see which companies compiled a list.
Get this free report